Phase
Condition
Diabetic Macular Edema
Macular Edema
Diabetic Retinopathy
Treatment
RGX-314 Dose 2
RGX-314 Dose 1
Aflibercept (2.0 mg)
Clinical Study ID
Ages 25-89 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Type I or Type II diabetes mellitus with center involving diabetic macular edemawith previous treatment
HbA1c ≤12%
BCVA in study eye 78 to 25 ETDRS letters (~20/32 to 20/320) at screening
Decreased visual acuity attributable primarily due to CI - DME
Demonstrate clinical response to aflibercept injection in the study eye
Provide written informed consent
Exclusion
Exclusion Criteria:
Women of childbearing potential
Neovascularization in the study eye from a cause other than DR
Evidence in the study eye of optic nerve pallor on clinical examination
History of pan retinal photocoagulation in the study eye
Any concurrent ocular condition in the study eye other than CI-DME that couldrequire surgical intervention within 6 months or any condition in the study eye thatmay increase the risk to the participant, require either medical or surgicalintervention during the study to prevent or treat vision loss, or interfere with thestudy procedures or assessments
Presence of an implant in the study eye at screening (excluding intraocular lens)
Any condition in the investigator's opinion that could limit VA improvement in thestudy eye
Active or history of glaucoma, steroid response, or ocular hypertension
Any prior intravitreal steroid injection in the study eye within 6 months prior toscreening, administration in the study eye of Ozudrex® within 12 months prior toscreening, or administration in the study eye if Iluven® within 36 months prior toscreening
Diabetic macular edema diagnosis ≥ 7 years
History of chronic renal failure requiring dialysis or kidney transplant
Participation in any other gene therapy study or receipt of any investigationalproduct within 30 days prior to enrollment or 5 half-lives of the investigationalproduct, whichever is longer, or any plans to use an investigational product within 6 months following enrollment
Note: Other inclusion/exclusion criteria apply
Study Design
Study Description
Connect with a study center
Sierra Eye Associates
Reno, Nevada 89502
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.